Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
1 of 46
Individualized Assessment and Treatment Program for TMD: 
Copi[INVESTIGATOR_25415] a Mechanism
Clinical Protocol
Protocol Number: 20-014-E
National Clinical Trial (NCT) Identified Number: [STUDY_ID_REMOVED]
Principal Investigator: [INVESTIGATOR_75712] D. Litt, PhD
Sponsor: UConn Health
IRB#: 23-052-1
Approved: 
Grant Title: Individualized Assessment and Treatment Program for TMD: 
Copi[INVESTIGATOR_25415] a Mechanism
Project Title: Mobile Application Treatment for TMD: Feasibility Trial
Grant Number: 3 U01 DE028520-03S1 (Supplement)
Funded by: [CONTACT_901282] (NIDCR)
1 September 2022
Version Number: 1.2
28 March 2023IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
2 of 46
Table of Contents
Statement of Compliance ............................................................................................................................................................4
Investigator's Signature ...........................................................................................................................................................4
1 Protocol Summary ....................................................................................................................................................................5
1.1 Synopsis .............................................................................................................................................................................5
1.2 Schema ..............................................................................................................................................................................7
1.3 Schedule of Activities.........................................................................................................................................................8
2 Introduction ..............................................................................................................................................................................9
2.1 Study Rationale..................................................................................................................................................................9
2.2 Background ........................................................................................................................................................................9
2.3.1 Known Potential Risks...............................................................................................................................................11
2.3.2 Known Potential Benefits .........................................................................................................................................12
2.3.3 Assessment of Potential Risks and Benefits..............................................................................................................12
3. Objectives and Endpoints ......................................................................................................................................................14
4 Study Design ...........................................................................................................................................................................15
4.1 Overall Design..................................................................................................................................................................15
4.2 Scientific Rationale for Study Design ...............................................................................................................................15
4.3 Justification for Intervention ...........................................................................................................................................15
4.4 End-of-Study Definition ...................................................................................................................................................15
5 Study SAMPLE.........................................................................................................................................................................16
5.1 Inclusion Criteria..............................................................................................................................................................16
5.2 Exclusion Criteria .............................................................................................................................................................16
5.3 Lifestyle Considerations...................................................................................................................................................16
5.4 Screen Failures.................................................................................................................................................................16
5.5 Strategies for Recruitment and Retention.......................................................................................................................17
6 Study Intervention(s) or Experimental Manipulation(s) .........................................................................................................18
6.1 Study Intervention(s) or Experimental Manipulation(s) Administration .........................................................................18
6.1.1 Study Intervention or Experimental Manipulation Description................................................................................18
MEASURES & INSTRUMENTS (See Table 1) .......................................................................................................................18
6.1.2 Administration and/or Dosing ..................................................................................................................................[ADDRESS_1264141] bias ....................................................................................................................................................22
6.4 Study Intervention/Experimental Manipulation Adherence ...........................................................................................22
6.5 Concomitant Therapy ......................................................................................................................................................23
6.5.1 Rescue Therapy.........................................................................................................................................................23
7 Study Intervention/Experimental Manipulation Discontinuation and Participant Discontinuation/Withdrawal ..................24
7.1 Discontinuation of Study Intervention/Experimental Manipulation ...............................................................................24
7.2 Participant Discontinuation/Withdrawal from the Study................................................................................................[ADDRESS_1264142] to Follow-Up.............................................................................................................................................................25
8 Study Assessments and Procedures .......................................................................................................................................26
8.1 Endpoint and Other Non-Safety Assessments .................................................................................................................26
8.2 Safety Assessments..........................................................................................................................................................26
8.3 Adverse Events and Serious Adverse Events ...................................................................................................................26
8.3.1 Definition of Adverse Events.....................................................................................................................................26
8.3.2 Definition of Serious Adverse Events........................................................................................................................26
8.3.3 Classification of an Adverse Event ............................................................................................................................27
8.3.4TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP...........................................................28IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264143]..........................................................................................................................................29
8.3.9 Reporting of Pregnancy ............................................................................................................................................29
8.4 Unanticipated Problems ..................................................................................................................................................29
8.4.1 Definition of Unanticipated Problems (UP) ..............................................................................................................29
8.4.2 Unanticipated Problems Reporting ..........................................................................................................................30
8.4.3 Reporting Unanticipated Problems to Participants ..................................................................................................30
9 Statistical Considerations........................................................................................................................................................31
9.1 Statistical Hypotheses......................................................................................................................................................31
9.2 Sample Size Determination..............................................................................................................................................31
9.3 Populations for Analyses..................................................................................................................................................32
9.4 Statistical Analyses...........................................................................................................................................................32
9.4.1 General Approach.....................................................................................................................................................32
9.4.2 Analysis of the Primary Endpoint(s)..........................................................................................................................32
Research Strategy..........................................................................................................................................................33
9.4.3 Analysis of the Secondary Endpoint(s)......................................................................................................................[ADDRESS_1264144] Policy......................................................................................................................................38
10.2 Additional Considerations..............................................................................................................................................39
10.3 Abbreviations and Special Terms...................................................................................................................................39
10.4 Protocol Amendment History ........................................................................................................................................40
11 References ............................................................................................................................................................................41IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
4 of 46
STATEMENT OF COMPLIANCE
The trial will be carried out in accordance with International Council on Harmonization Good Clinical Practice 
(ICH GCP) and the following:
o[LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR 
Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).
National Institutes of Health (NIH)-funded investigators and clinical trial site staff who are responsible 
for the conduct, management, or oversight of NIH-funded clinical trials have completed Human Subjects 
Protection and ICH GCP Training.
INVESTIGATOR'S SIGNATURE
[INVESTIGATOR_678] [INVESTIGATOR_9095]:
Signed:
 Date: 9/15/2022
Name: [INVESTIGATOR_75712] D. Litt, PhD
Title: Professor of Behavioral Sciences
Investigator Contact [CONTACT_7171]:
Affiliation:  University of Connecticut Schools of Medicine and Dental Medicine
Address:  Division of Behavioral Sciences & Community Health - MC3910
Farmington, CT   [ZIP_CODE]
Telephone:  [PHONE_18686]
Email:  [EMAIL_17187] Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
5 of 46
1 PROTOCOL SUMMARY
1.1 SYNOPSIS
Title: Individualized Assessment and Treatment Program for TMD: Copi[INVESTIGATOR_528326] a Mechanism
Grant Number:   1 R01 DE028520
Study Description: This is a proposal for an administrative supplement to the parent 
study, “Individualized Assessment and Treatment Program for TMD: 
Copi[INVESTIGATOR_25415] a Mechanism” (U01 DE028520). The parent study is 
currently engaged in exploring the extent to which the training of 
copi[INVESTIGATOR_901226]. The current project seeks to lay the groundwork for 
expanding the range of treatment mechanisms examined to include 
therapeutic relationship factors (therapi[INVESTIGATOR_34722], empathy,  
acknowledgment). 
Psychosocial treatments have been effective for 
temporomandibular disorders (TMD), but the mechanisms of action 
for these treatments are unclear. Most studies of psychosocial 
treatment, including the parent U01, have focused on relatively 
specific psychosocial mechanisms, including copi[INVESTIGATOR_901227], 
pain management self-efficacy, decrease in catastrophizing, increased 
mindfulness, acceptance, and readiness to change behavior to 
ameliorate pain. The [ADDRESS_1264145]-delivered treatments in the parent 
study are packaged CBT or Individualized Assessment and Treatment 
(IATP). Left untested in this study are common therapeutic factors 
that often emerge as influential in pain outcome research. These 
common, non-specific therapeutic factors include (especially): the 
therapeutic alliance; interpretation and understanding; emotional 
expression; reinforcement; information; and reassurance and 
support. Because both conditions of the parent U01 involve similar 
levels of therapi[INVESTIGATOR_332214], therapi[INVESTIGATOR_901228]-non-specific variables cannot be tested clearly. One way to 
assess these factors is to introduce a pain treatment that explicitly 
does not contain these factors; i.e., a treatment that does not employ 
therapi[INVESTIGATOR_901229]. There 
are currently no studies published in which therapi[INVESTIGATOR_541]-led treatments 
have been compared to a mobile application-based treatment. 
We therefore propose to pi[INVESTIGATOR_21087] a mobile application treatment 
condition (painTrainer©) added as an additional treatment condition 
to the parent study, and provided to [ADDRESS_1264146] support factors. An IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
6 of 46
additional benefit of testing such a mobile application is that it might 
in the future provide a means to expand the reach of pain 
management professionals to remote and underserved populations. 
Objectives*: Primary Objective: To test the feasibility, acceptability, and 
credibility of a mobile app treatment for 
chronic TMD/orofacial pain relative to 
treatment delivered by [CONTACT_361233][INVESTIGATOR_11437].
Secondary Objectives:
Tertiary/Exploratory
Objectives:To examine preliminary differences in 
specific (e.g., copi[INVESTIGATOR_4262]) and non-
specific treatment effects (e.g., working 
alliance, perceived support-empathy), 
between the therapi[INVESTIGATOR_541]-delivered treatments 
and the MobileApp treatment
The MobileApp condition will show some 
therapeutic effects on TMD/orofacial pain 
symptoms.
Endpoints*: Primary Endpoints: Treatment Feasibility
Treatment Acceptability 
Treatment Credibility
Treatment Adherence
Secondary Endpoints:
Tertiary/Exploratory
Endpoints:Pain ratings
Therapeutic alliance
Parafunctional Habits
Somatization
Social Support
Mood/Neuroticism
Acceptance
Stage of Change/Motivation
Study Sample: 20 men and women with a complaint of orofacial pain (> 3 on 0-10 
scale for pain) of at least 3mo duration; minimum age 18 years; 
residing in greater Hartford, CT, area to permit frequent visits for 
treatment and follow-up. Those with pain of odontogenic or 
neuropathic origin, diagnosed with psychosis, taking narcotic pain 
medication, or those pregnant or intending to become pregnant will 
be excluded. 
Stage: 1
Description of Sites/Facilities 
Enrolling Participants:UConn Health is the state medical center for the State of Connecticut, 
[LOCATION_003]. Patients will be seen exclusively at UConn Health, in the Dental 
Clinical Research Center, in Oral Radiology, and in therapy offices in 
the main hospi[INVESTIGATOR_359879].IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
7 of 46
Description of Study 
Intervention/Experimental 
Manipulation:painTRAINER (MobileApp condition)
A 6-session web-based mobile pain management application 
comprised of [ADDRESS_1264147] presence. 
Study Duration: 14 months
Participant Duration: 10-12 Weeks
1.2 SCHEMA
Design and Timeline of procedures
Session/Time Point
Treatment Baseline Treatment  
Condition Wk -1, [ADDRESS_1264148]-Tx 
Measures
Treatment 
AssignmentSplint 
Delivered Splint Taper -
night onlySplint
Discont’d  
 
Impressions 
for splintpainTRAINER 
Patients
Session 1painTRAINER 
Patients 
Session 2painTRAINER 
Patients 
Session 4painTRAINER 
Patients 
Session 5painTRAINER 
Patients 
Session 6 
 
 Start NSAIDs Taper NSAIDs      
 
 
 
 painTRAINER
4 Times 
Daily 
Monitoring
(14 Days) 4 Times Daily 
Monitoring
(7 days)4 Times Daily 
Monitoring
(7 days)  4 Times 
Daily 
Monitoring
(7 days)IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
8 of 46
1.3 SCHEDULE OF ACTIVITIES
TMD 3c: Schedule of Activities
Visit/session Week Participant Activity
1 -3 to -2 Potential Participant is initially screened for eligibility via telephone, or in person (e.g., in dental clinic)
2 -2 Diagnostic Evaluation (DE) visit (2 – 2.5 hours):
·  Orofacial Examination; Panoramic x-ray, impressions for splint taken
·  Administration of baseline measures (e.g., SCID, Orofacial pain and function)
·  Treatment Assignment
·  Introduction to Experience Sampling - Monitoring  X 4 daily via smartphone (X 14 days; completed by 
[CONTACT_263318])
3 1 – 3* Splint is delivered
NSAIDs started (e.g., naproxen 550mg po BID)
Soft diet guidance given to patient
painTRAINER website is loaded and bookmarked on patient smartphone
Pt. completes tutorial and painTRAINER sessions 1 and 2   (TMD Online Session 1)
4 2 – 4* painTRAINER session 3 (TMD Online Session 2)
Start to taper NSAIDs
Re-start Experience Sampling - Monitoring  X 4 daily via smartphone X 7 days
5 3 – 5* painTRAINER session 4 (TMD Online Session 3)
6 4 – 6* Taper splint (e.g., wear as night guard only)
painTRAINER session 5 (TMD Online Session 4)
Re-start Experience Sampling - Monitoring  X 4 daily via smartphone X 7 days
7 5 – 7* Splint discontinued
painTRAINER session 6(TMD Online Session 5)
8 6 – 10* painTRAINER sessions 7 and 8 (TMD Online Session 6)
9 11-14 * Administration of Posttreatment Self-Report Measures
Re-start Experience Sampling - Monitoring  X 4 daily via smartphone X 7 days
*Recognizing variability in schedules of working adults, flexibility is allowed in completion of study activities. Patients will have 10 weeks 
to complete the 6 treatment sessions. The Treatment and follow-up sessions will be conducted remotely.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
9 of 46
2 INTRODUCTION
2.1 STUDY RATIONALE
Temporomandibular/orofacial pain disorders (TMD) are a group of painful conditions with multiple 
determinants. A number of psychosocial treatments for TMD have been developed, but overall effectiveness has 
been limited, and the mechanisms of treatment are unknown. Psychosocial treatments have been effective for 
temporomandibular disorders (TMD), but the mechanisms of action for these treatments are unclear. 
Most studies of psychosocial treatment, including the parent U01, have focused on relatively specific 
psychosocial mechanisms, including copi[INVESTIGATOR_901227], pain management self-efficacy, decrease in 
catastrophizing, increased mindfulness, acceptance, and readiness to change behavior to ameliorate pain. The [ADDRESS_1264149]-delivered treatments in the parent study are packaged CBT or Individualized Assessment and 
Treatment (IATP). Left untested in this study are common therapeutic factors that often emerge as influential in 
pain outcome research. These common, non-specific therapeutic factors include (especially): the therapeutic 
alliance; interpretation and understanding; emotional expression; reinforcement; information; and reassurance 
and support. Because both conditions of the parent U01 involve similar levels of therapi[INVESTIGATOR_332214], therapi[INVESTIGATOR_901230]-non-specific variables cannot be tested clearly. One way to assess these factors is 
to introduce a pain treatment that explicitly does not contain these factors; i.e., a treatment that does not 
employ therapi[INVESTIGATOR_901229]. There are currently no studies published 
in which therapi[INVESTIGATOR_541]-led treatments have been compared to a mobile application-based treatment. 
We therefore propose to pi[INVESTIGATOR_21087] a mobile application treatment condition (painTrainer©) added as an 
additional treatment condition to the parent study, and provided to [ADDRESS_1264150]-related mechanisms of 
psychosocial treatment for TMD/orofacial pain. Such information will eventually allow us to test treatments that 
capi[INVESTIGATOR_901231]. Additionally, however, if a credible and acceptable mobile app can 
approximate effects achieved with therapi[INVESTIGATOR_11437], then access to pain management could be greatly extended to 
many patients we currently do not reach.
2.2 BACKGROUND
TMD/Orofacial pain from a biopsychosocial perspective.  Studies of the symptoms, course, and treatment of 
TMD indicate that the disorder shares much in common with other chronic, ill-defined pain problems such as 
headache and back pain. The disorder appears to be multiply determined, with both psychosocial and physical 
factors playing a role in the development and maintenance of the disorder (Flor & Turk, 2011; Harper et al., 
2016). Although persistent pain is the cardinal feature of TMD, stress, depression, disability and dysfunctional IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
10 of 46
illness are also significant aspects (Dworkin & Massoth, 1994). Also in common with headache and back pain is 
the finding that a variety of treatments have shown success with some patients. Among the more effective of 
these are cognitive-behavioral treatments (CBT) (Ehde et al., 2014; Gupta et al., 2019; Häggman-Henrikson et al., 
2020; Randhawa et al., 2016). Despi[INVESTIGATOR_901232], however, the mechanisms by [CONTACT_901283]. 
Mechanisms of action of CBT. Cognitive-behavioral treatments (CBT) presumably improve pain by [CONTACT_901284] (in particular, catastrophizing) that exacerbate pain, and by [CONTACT_901285][INVESTIGATOR_007] (Turk et al., 1983; Turner & Romano, 2001). These changes should in turn lead to 
improvements is confidence (self-efficacy) for pain management (Jensen et al., 1991) and improvements in 
momentary and durable mood states (Litt et al., 2009; Litt et al., 2010). This is a compelling model. However, 
relatively little research has been conducted to determine if cognitive-behavioral treatments actually lead to 
these kinds of changes, and if so, whether those changes are accounting for symptom reduction (Burns et al., 
2020). What research has been done has not shown consistent mechanism effects for the acquisition of pain 
copi[INVESTIGATOR_25110] (Aggarwal et al., 2010). The evidence does suggest outcomes might be improved if copi[INVESTIGATOR_901233] a more effective manner, and tailored to individual strengths and weaknesses. What is less clear 
is whether even adaptive changes in cognitions, affects, and behavior can account for all of the treatment 
effects seen in CBT-oriented interventions.
Other potential mechanisms: Common factors and common therapi[INVESTIGATOR_695854]. Somewhat contrary to the idea 
that specific aspects of treatment (e.g., copi[INVESTIGATOR_25125]; cognitive control) are responsible for adaptive 
change in pain, the common factors model suggests that factors common to all treatments are responsible for 
producing treatment-related changes (Burns, 2016). Five classes of common factors are usually identified: 
change processes (e.g., expectancies), therapi[INVESTIGATOR_901234] (perceived competence), relationship elements 
(therapi[INVESTIGATOR_169394], empathy, support), treatment structures (e.g., predictability), and client characteristics 
(Cosio, 2016). Outside of client factors (e.g., sex, motivation), the greatest source of common variance are 
therapi[INVESTIGATOR_695854], accounting for perhaps 30% of treatment effects (Hubble et al., 1999). These common 
therapi[INVESTIGATOR_901235]: (especially) the therapeutic alliance; interpretation and understanding; emotional 
expression; reinforcement; information; and reassurance and support (Garfield, 1995; Imel & Wampold, 2008). 
Although the common therapi[INVESTIGATOR_901236], it is not clear how they translate into initial 
or prolonged behavior change or adaptation. Presumably, support and reinforcement for adaptive behavior 
when in company with others will improve mood and increase self-efficacy for copi[INVESTIGATOR_901237]. 
The influence of common, or therapi[INVESTIGATOR_541], factors is difficult to determine from most trials, however, because 
almost all treatments in these trials are delivered by [CONTACT_2111][INVESTIGATOR_11437]. Thus, therapi[INVESTIGATOR_901238]. To assess the influence of therapi[INVESTIGATOR_695854], treatment would have to 
be provided that was identical in content, but that did not involve interaction with a therapi[INVESTIGATOR_541]. 
The Parent Study: TMD3c U01DE028520. The parent study, “Individualized Assessment and Treatment Program 
for TMD: Copi[INVESTIGATOR_25415] a Mechanism” (U01 DE028520), is currently engaged in exploring the extent to which copi[INVESTIGATOR_25146], if tailored to the patient, can effect improvements in chronic pain and functioning. This is considered a 
significant test of the social learning model of pain management. To do this, a highly individualized copi[INVESTIGATOR_901239]’ own reports of their pain and copi[INVESTIGATOR_901240]-time. This 
treatment, Individualized Assessment and Treatment (IATP) is being tested against a more conventional, or 
packaged, cognitive-behavioral treatment program (CBT) that covers typi[INVESTIGATOR_901241] a fixed format. The present Supplement application. The current supplement application seeks 
to expand the range of treatment mechanisms examined to include therapeutic relationship factors (therapi[INVESTIGATOR_901242], empathy, respect, acknowledgment). Despi[INVESTIGATOR_901243], the design is not 
optimal to detect the influence of therapi[INVESTIGATOR_901244]. Because both conditions of the parent IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264151] been studied by [CONTACT_901286][INVESTIGATOR_11437] (Martin et al., 2021). Mobile applications do, however, have promise to 
deliver some pain reduction (Irvine et al., 2015), as well as amelioration of anxiety (Bhatia et al., 2021), to a 
widespread population without the need for medical or therapi[INVESTIGATOR_20790]. If successful, these can greatly 
improve access to care.
Significance
The addition of a treatment condition delivered without therapi[INVESTIGATOR_901245]. This 
project will offer an opportunity to pi[INVESTIGATOR_21087] a mobile program for TMD pain in controlled circumstances, against 
treatments delivered by [CONTACT_21724]. If a credible and acceptable mobile application is demonstrated with 
these pi[INVESTIGATOR_901246] a basis for a full-scale trial. Eventually we hope to determine the 
importance of specific content and skills, above and beyond the influence of common therapi[INVESTIGATOR_25119]. In 
addition, however, this pi[INVESTIGATOR_901247].
2.3.1 KNOWN POTENTIAL RISKS
There are no serious risks associated with participation in this research. Minor risks are as follows:
1. Clinical Deterioration. As with any treatment for a medical issue, participants could experience clinical 
deterioration (worsening of pain or other life issue) during the course of the study, especially if the 
treatment to which one is assigned is not effective in any specific case. 
2. Panoramic X-Ray. In order to rule out jaw disorders, participants will undergo a panoramic x-ray, which 
exposes participants to radiation. 
3. Discomfort with Splint. All participants will be fitted with a splint, or mouth guard, placed on the upper 
teeth. Some people may find this uncomfortable, especially at first. 
4. Confidentiality/Risk of unauthorized disclosure of confidential material. Another potential risk is a possible 
breach of confidentiality.
5. Risk of gastrointestinal upset secondary to taking NSAIDs (naproxen sodium 550 mg po BID; or 400 mg 
Ibuprofen BID or TID X 14 days). Use of NSAIDs like those proposed for this study carry a small (less than 
10%) risk of causing GI distress. This medication is also contraindicated for those with kidney disease. 
Subjects with known sensitivity to NSAIDs, those with documented kidney disease, or those who experience 
GI upset during the course of the study may be placed on acetaminophen as an analgesic, in consultation 
with the patient’s physician. IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264152] as helpi[INVESTIGATOR_901248]. We believe that 
the small potential risks are outweighed by [CONTACT_901287]-monitoring that may 
accrue to participants in the study.  
2.3.3 ASSESSMENT OF POTENTIAL RISKS AND BENEFITS
Rationale for the necessity of exposing participants to risks: 
TMD/Orofacial pain problems are widespread. This research has potential to deliver a new, more effective 
treatment, and to expose important mechanisms that can be used in treatments for others. The small potential 
risks are outweighed by [CONTACT_901287]-monitoring that may accrue to participants 
in the study. There may also be long-range benefits for improved treatment of TMD for others as a result of this 
study. Results may also be applicable to other, similar, pain problems. 
A summary of the ways that risks to participants were minimized in the study design: 
1. Clinical Deterioration. The research staff will monitor participants in for signs of deterioration, and will 
refer participants for more intensive treatment if such a problem arises. If participants pursue treatment 
outside the study, they will be responsible for the costs of that treatment.
2. Panoramic X-Ray. The estimated radiation exposure received by [CONTACT_901288] 1.5 millirem (15 uSv). This dose equivalent would be less than that received by [CONTACT_901289].
3. Discomfort with Splint. All participants will be fitted with a splint, or mouth guard, placed on the upper 
teeth. Participants will be instructed that they may stop using the splint at any time. Some people may 
find the splint uncomfortable at first. If discomfort occurs, participants will be instructed to contact [CONTACT_901290], so that study staff can arrange for a prompt visit (within a 
couple of days) to make adjustments to the splint. If the discomfort continues, participants may 
discontinue using the splint
4. Confidentiality/Risk of unauthorized disclosure of confidential material. Study staff will make every 
effort to maintain participants’ confidentiality. Research records will be labeled with a code number, 
which will be determined using a random numbers list. A master list that links participants’ names with 
their code number will be maintained in a separate and secure location. Consent forms in electronic 
form will be stored in a secured location (a secure server) apart from the research record. Participants’ 
names will not appear in any publication. Only research staff associated with this study will have access 
to the research record, or to the master list linking participants’ names with code numbers. If 
participants’ information is used in future research, all identifiers, such as name [CONTACT_18131], will be 
removed. After removal of names and other identifiers, the information participants provide could be 
used for future research studies or distributed to another investigator for future research studies 
without additional informed consent from participants.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
13 of 46
5. Risk of gastrointestinal upset secondary to taking NSAIDs (naproxen sodium 550 mg po BID; or 400-600 
mg Ibuprofen BID or TID X 14 days). Participants with known sensitivity to NSAIDs, those with 
documented kidney disease, or those who experience GI upset during the course of the study may be 
placed on acetaminophen as an analgesic, in consultation with the patient’s physician. IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264153] the feasibility 
and acceptability of a 
mobile app treatment 
for chronic 
TMD/orofacial pain1. Patient acceptance 
of assignment to 
treatment 
2. Scores on Treatment 
Acceptability scale
3. Scores on Treatment 
Credibility scale
4. Patient adherence to 
treatment assignmentsThis is a feasibility study. 
The primary endpoints are 
thus treatment 
acceptability, credibility 
and feasibility of the 
procedures. A mobile app for pain 
management should deliver 
the didactic content of a 
CBT program, and will also 
prompt patient to monitor 
their own progress, without 
having to travel or make 
time to see a therapi[INVESTIGATOR_541].
Secondary
To determine if patients 
given this treatment 
record reduced pain 
and interference with 
lifestyle 1.Graded chronic pain 
score
2.Jaw Functional 
Limitation Scale-
Short form (JFLS)
3.MPI - Interference
4.CES-D
5.STAI-Trait
6.Pt Global Impression 
of ChangeAlthough power will not be 
sufficient to determine if 
this treatment is 
efficacious, we do expect 
some improvement in 
symptoms. painTRAINER is designed to 
provide skills that patients 
can use to manage their 
pain. The program allows 
them to monitor their 
progress and adjust their 
behavior as necessary. 
These activities should 
result in reduced pain and 
improved functioning 
Tertiary/Exploratory
NoneIRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264154] the study hypotheses for a feasibility trial:
 (1) The mobile application (painTrainer) will prove to be a feasible and acceptable intervention, as evidenced by 
[CONTACT_901291] a reasonable time span, and agreeing to treatment using the 
application.
(2a) The mobile application (painTrainer) will prove to be a credible treatment, as evidenced by [CONTACT_901292] a 
measure of treatment credibility (the treatment credibility/expectancy questionnaire), as compared against 
published credibility scores. 
(2b) The mobile application (painTrainer) will prove to be as credible as the therapi[INVESTIGATOR_541]-led treatments currently 
provided in the Parent study, as demonstrated by [CONTACT_901293]-inferiority on credibility scores. 
(3) Patients in the MobileApp will show acceptable adherence to the scheduled procedures, as evidenced by 
[CONTACT_901292] a treatment adherence measure, and through completion of exercises monitored by [CONTACT_901294] (i.e., > 80% completion of recommended exercises).  
4.[ADDRESS_1264155] visit (posttreatment visit) as shown in the Schedule of Activities (SoA), Section 1.3.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
16 of 46
5 STUDY SAMPLE
5.1 INCLUSION CRITERIA
Inclusion criteria are as follows:
Age at least 18 years
Complaint of either bilateral or unilateral pain, scoring > 3 on a 11-point pain scale (scored from 0 to 10), in 
the area of the temporomandibular joint
Pain has persisted for a period of at least 3 months by [CONTACT_18654]-report. Pain may be constant or 
intermittent.
5.2 EXCLUSION CRITERIA
Exclusion criteria:
Contraindications to TMD treatment (as determined by [CONTACT_901295])
Inadequate fluency in English
History of prior surgery for TMD
Receiving concurrent treatment for orofacial pain (including orthodontic or physical therapy)
Have a condition that requires the use of an oral appliance (e.g., sleep apnea)
Diagnosed as having pain of neuropathic or odontogenic origin
History of rheumatoid disease or autoimmune disease (e.g., rheumatoid arthritis; lupus) currently being 
treated with anti-inflammatory drugs
History of kidney disease or current kidney issues
Extensive anatomical destruction or deterioration of the TM joint
Current treatment of chronic pain issue with anti-inflammatories (e.g., Indomethacin; methotrexate; 
dexamethasone) or opi[INVESTIGATOR_2467]
Carrying a diagnosis of psychosisa (as per self-report on Quick Screen)
Pregnant or anticipating pregnancy (due to prescription of NSAIDs)
aAmong persons carrying a diagnosis of psychosis it may be difficult to parse symptoms attributable to the 
psychosis from those attributable to pain. In addition,  those with psychosis tend to report less pain than non-
psychotic persons (Singh et al., 2006). Thus those with psychosis will be excluded
5.3 LIFESTYLE CONSIDERATIONS
During treatment all patients will be advised to:
1. Alter their diets to avoid chewy foods or those difficult to chew, and to choose soft foods
2. Wear the intraoral splint full time if possible x [ADDRESS_1264156] hours of splint use per day. 
These lifestyle alterations are considered “homework,” and will be monitored for adherence weekly. Patients 
who do not adhere to these recommendations will not be dropped from the study. Adherence to medication, 
diet and splint use will be used as covariates in analyses of outcomes. 
5.4 SCREEN FAILURES
Screen failures are defined as participants who consent to participate in this study but are not subsequently 
assigned to the study intervention or entered in the study. Individuals who do not meet the criteria for IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
17 of 46
participation in this trial (screen failure) because of meeting one or more exclusion criteria that are likely to 
change over time may be rescreened. Examples include a change in plans to become pregnant during the course 
of the study or lifting of physical activity restrictions previously in place. Rescreened participants will be assigned 
the same participant number as determined in their initial screening.
5.[ADDRESS_1264157] different TMD treatments. Those interested will be 
screened over the telephone for basic inclusion/exclusion criteria. Those who meet eligibility at this point will be 
scheduled within 14 days for a diagnostic evaluation (DE). A remote consent process will then be conducted over 
the phone, with documentation of consent enabled via REDCap. 
Consent Process. Those persons who appear to be eligible on the Quick Screen will be e-mailed a link to a 
REDcap version of the informed consent form prior to any assessment. The REDCap system can be accessed 
using a smart phone, computer, laptop, or tablet device. REDCap (Research Electronic Data Capture) is a secure, 
HIPAA-compliant, web-based application. An electronic file that links patient name [CONTACT_901324]. A research 
assistant will schedule a time with the participant to review the consent form on the telephone as the 
participant reads it to assure comprehension. The REDcap form will allow addition of an e-signature [CONTACT_901325], as well as a signature [CONTACT_901326]. Those who 
request being allowed to read and sign the consent form in person will be scheduled for an appointment at 
UConn Health solely for the consent process. Persons meeting initial eligibility criteria and consented will be 
scheduled for a baseline diagnostic evaluation session (DE) 
Baseline session - DE. The DE will consist of questionnaires administered to the participant by [CONTACT_21171] 
(RAs), as well as a clinical evaluation of the orofacial pain problem conducted in the dental clinic by [CONTACT_901296] (i.e., the participating dentists). Questionnaires will be administered via REDCap, with assistance by [CONTACT_901297]. 
The clinical examination will be conducted in the dental clinic of the Dental Clinical Research Center of UConn 
Health. At this session potential subjects will be examined by [CONTACT_901298](s) who will rule out 
neuropathic or odontogenic pain and diagnose the type of orofacial pain according to the Diagnostic Criteria for 
TMD (DC/TMD). Following this examination prospective subjects will have a panoramic X-ray taken to rule out 
gross arthritic or anatomic damage to the TM joint. For those meeting criteria by [CONTACT_261031]/TMD impressions will 
be taken for an acrylic, flat-plane disoccluding splint. Subjects will be given $[ADDRESS_1264158] e-mailed to the participant, if 
possible.
Posttreatment Data Collection. At the 6 weeks point (or after [ADDRESS_1264159] been completed) patients will be 
asked to complete follow-versions of the dependent measures. At this point, subjects will once again be asked 
to participate in ES via smartphone app for 7 days to determine if situation-specific copi[INVESTIGATOR_901249]. $25 will be offered for Posttreatment data collection + up to $[ADDRESS_1264160] e-mailed to the participant, if possible.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
18 of 46
6 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S)
6.1 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S) ADMINISTRATION
6.1.1 STUDY INTERVENTION OR EXPERIMENTAL MANIPULATION DESCRIPTION
MEASURES & INSTRUMENTS (SEE TABLE 1)
TMD Diagnostic Protocol: Screening and Classification (SCID & DC/TMD Axes I and II)
Initial screening of potential subjects will be conducted over the telephone using an inclusion/exclusion criteria 
checklist administered by a research associate. Potential participants will receive e-mail links to complete 
questionnaires via REDCap. Screening questionnaires administered remotely will include the psychotic screening 
portion of the Structured Clinical Interview for DSM-V (SCID-V; First et al., 2015), plus the DSM-5 Self-Rated 
Level 1 Cross-Cutting Symptom Measure—Adult (Association, 2013), which can screen for a variety of psychiatric 
issues, including depression, suicidal ideation, anxiety, and sleep disturbances, among others. Classification of 
TMD subjects’ orofacial pain problem will be done using the revised Diagnostic Criteria for Temporomandibular 
Disorders History Questionnaires (Ohrbach R. (Editor), Version 15May2016; Schiffman et al., 2014). The DC/TMD 
procedures are an update of procedures laid out by [CONTACT_901299] & LeResche (1992), with increased sensitivity and 
reliability of diagnoses, particularly in Axis I. The examination will be conducted by [CONTACT_901300], who have experience with the DC/TMD examination. Prior to patient 
recruitment the examiners will train on sample cases using the DC/TMD procedures manual until they attain 
90% interrater agreement on specific Axis I diagnoses. During the recruitment phase the examiners will test on 
each 20th case to maintain reliability. DC/TMD Axis II assessment will be conducted using the following, as per 
the assessment manual, and administered remotely via REDCap: The Jaw Function Limitation Scale (JFLS-20; 
Ohrbach, Granger, et al., 2008); The Patient Health Questionnaire (PHQ-15; Kroenke et al., 2002); The General 
Anxiety Disorders scale (GAD-7; Spi[INVESTIGATOR_72443]., 2006); and the Oral Behaviors Checklist (Ohrbach, Markiewicz, et 
al., 2008). In addition to the above, we will also collect information on any use of concomitant medications, at 
intake and at each follow-up, as well as non-protocol concomitant treatments for orofacial pain patients may 
have sought. See Table 3 for schedule of instrument administration. 
Dependent Variables (IMMPACT recommendations)
Primary Dependent Variables. The same battery of dependent measures used in the Parent study will be 
administered to the MobileApp patients recruited for this Supplement.  However, due to the preliminary nature 
of this study, the primary dependent variables will be those tied to feasibility and acceptability. Patients  in this 
study will be administered the Treatment Acceptability and Adherence Scale (TAAS) (Milosevic et al., 2015) to 
assess treatment acceptability. The TAAS is in widespread used. Credibility of the treatments will be assessed 
using the Credibility/Expectancy questionnaire (CEQ) by [CONTACT_901301] & Borkovec (2000). The CEQ is the most widely 
used measure of treatment credibility and expectancy in psychotherapy research (Thompson-Hollands et al., 
2014). These two measures will serve as outcomes relevant for the MobileApp condition
Supplemental Dependent Variables. The supplemental dependent variables in this study will be Pain Intensity, 
Depression and Interference. A number of secondary outcomes will also be assessed and analyzed as per 
guidelines from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT; 
Haythornthwaite, 2010; Turk et al., 2003). All outcomes will be evaluated on day of recruitment (baseline) and 
again at the posttreatment point. The six outcome domains are: (1) pain (including intensity and pain 
experience); (2) physical functioning; (3) emotional functioning; (4) participant ratings of improvement and 
satisfaction with treatment; (5) symptoms and adverse events; and (6) participant disposition (e.g. adherence to IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
19 of 46
treatment, reasons for premature withdrawal). Specific instruments were chosen on the basis of 
recommendations by [CONTACT_901302]. (2010). Several instruments were included because they have 
proven useful in our previous studies, and may form a basis for comparison. All instruments chosen have 
demonstrated acceptable psychometric characteristics. 
An additional process measure, the debriefing questionnaire, will be administered at posttreatment to help us 
determine whether the painTRAINER treatment program efficacy might be enhanced with the addition of some 
therapi[INVESTIGATOR_901250]. 
IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264161] week from the Graded Chronic Pain Scale (GCPS; Von Korff 
et al., 1992); a reliable retrospective measure (Stone et al., 1997). Each item is scored from 0 -10. Other 
dimensions of pain per se, (sensory and affective dimensions), will be assessed using the short form of the 
McGill Pain Questionnaire (MPQ-SF; Melzack, 1987).
Physical functioning. General interference with activities will be measured using the interference scale from the 
Multidimensional Pain Inventory (MPI; Kerns et al., 1985). The MPI [INVESTIGATOR_901251], which is 
often affected in pain patients. Jaw function will be assessed using the Jaw Functional Limitation Scale (JFLS; 
Ohrbach et al., 2008). The JFLS is a 20-item questionnaire that assesses mastication, jaw mobility, and verbal and 
emotional communication. 
Emotional functioning. Depression symptoms will be measured using the using the 20-item Center for 
Epi[INVESTIGATOR_901252] (CESD-R; Eaton et al., 2004), a useful measure of distress in 
medical populations. In addition we will measure anxiety mood using the Trait version of the State-Trait Anxiety 
Inventory (STAI) (Spi[INVESTIGATOR_57601]., 1983).  Participant rating of improvement will be assessed with the Patient 
Global Impression of Change scale (PGIC; Hurst & Bolton, 2004). The PGIC consists of two questions in two 
different formats asking for a global assessment of “change if any, in activity limitations, symptoms, emotions 
and overall quality of life.” A 2-point change on the rating scale has been calculated to be clinically significant. 
Symptoms and adverse events will be collected weekly during treatment and at each follow-up by [CONTACT_802128]. Procedures are described in the Human Subjects section. Participant disposition, including retention 
in treatment and follow-ups, and reasons for withdrawing, will be collected in a patient tracking database. 
Dispositional Variables-Moderators/Mediators
The Parent study contains measures of dispositional moderators based on past research. These include 
measures of Copi[INVESTIGATOR_007], Catastrophizing, Acceptance, Somatization, Neuroticism, Readiness to change, and Self-
efficacy. General copi[INVESTIGATOR_901253] (BCPI; McCracken et al., 2005). 
Common factors: As has been suggested here, the effectiveness of therapy is may be significantly attributable to 
the therapeutic relationship. We are already administering the Working Alliance Inventory (Short Form)  (WAI; 
Horvath & Greenberg, 1986) to assess therapeutic alliance. To this we will add [ADDRESS_1264162] empathy, from the MOPQ Common Factors Questionnaire (Finsrud et al., 2022). Although the 
MobileApp patients will not have a therapi[INVESTIGATOR_901254], the questions will be altered to refer to “Treatment Staff.”
Experience Sampling (ES) of pain, copi[INVESTIGATOR_007], and affects via Smartphone app
As in the treatment conditions currently being run in the Parent study, patients in the MobileApp condition will 
also engage in Experience Sampling of pain, affect, cognitions and copi[INVESTIGATOR_610], so that this aspect of 
treatment will be equivalent across conditions. The MobileApp patients will be monitored using the same 
MetricWire application as the rest of the patients. Just as in the STD+CBT condition, those in the MobileApp 
condition will be asked to make momentary recordings, but those recordings will not be used to influence 
treatment. This recording approach was designed to not be reactive, by [CONTACT_53737][INVESTIGATOR_901255] (Barta et al., 2011). 
During an initial training session participants will be instructed to answer each question with as  little reflection 
as possible. Participants will be asked to carry their phone at all times between 8AM and 10PM in Weeks -1 and 
0 (after  baseline interviews, but before treatment starts), for 7 days during weeks 2 & 4 while in treatment, and 
again for 7 days after completion of treatment, and later during the follow-up (See above: Schedule of 
Activities). The smartphone-based ES system will administer surveys and record responses. The system will be IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
21 of 46
programmed to prompt subjects on a quasi-random basis 4 times per day, with one randomly scheduled prompt 
in each of four 210-minute time periods from 8:00AM to 10:00PM (adjustable for different schedules). This 
frequency of recording was chosen to enable us to capture as many moments in a  patient’s day as possible 
without being disruptive (Litt et al., 2004; Litt et al., 2010). Subjects will have the option of  delaying responding 
to a prompt for 5, 10 or 15 minutes if recording is inconvenient.  Delays longer than 15 minutes will be classified 
as missing. 
As in the parent study, participants will earn $5.00/day for every day of satisfactory experience sampling 
recording (i.e., > 3 recordings per day).  A bonus of $5.00 will be paid in a week in which > 3 recordings were 
made every day, for a possible total of $40.[ADDRESS_1264163] perceptions along a 6-point “slide-scale” ranging from "0=Not at all" to "5=Very  
much." Responses are time-and-date-stamped, and entry of out-of-range data is not possible. If data entry is 
abandoned in the midst of an assessment, the system will prompt the participant again and resume the 
assessment. Assessment data will be electronically stored in spreadsheet format on a system server maintained 
by [CONTACT_901303], backed up nightly, and accessible to our study team in real time. Data from each 
participant engaged in ES monitoring will be examined periodically for missing responses by a research assistant. 
If a participant misses two recordings in a row, the research assistant will contact [CONTACT_901304].  
ES data. Patients will respond during ES to items related to pain intensity (right and left sides of the face) and  
unpleasantness experienced (right and left sides), and two items related to perceived control over pain (“am 
able to decrease pain;” “am able to control pain”). Self-efficacy will be measured with: “How confident are you 
that you can cope with your current pain?” Catastrophization will be assessed using two items borrowed and  
modified from the Copi[INVESTIGATOR_100779] (CSQ; Rosenstiel & Keefe, 1983) catastrophization  subscale, 
are “Worried about Pain” and “Pain is Terrible,” (α = .87). Somaticizing will be measured using 2 items reflecting 
the tendency to process stress in terms of physical symptoms: “Concerned that jaw will start  hurting,” “Paying 
attention to my jaw pain.”  Current mood state will be recorded using 8 items derived from a semantic space 
analysis of adjectives in the  circumplex model of affective experience (Larsen & Diener, 1992; Russell, 1980). 
The items are combined to yield four reliable mood composites based on dimensions of pleasantness and 
arousal.  Situations will be assessed using categories (Home, With others, etc.), as well as with free voice 
response.  Copi[INVESTIGATOR_901256]/she might have experienced in the last 10 minutes. The 11 copi[INVESTIGATOR_901257] (e.g., the CSQ), and from surveys of patients in TMD 
pain treatment, and grouped into 4 subscales: active-behavioral (e.g., “I used ice or heat,” “Relaxed”); active-
cognitive  (e.g., “I thought pleasant thoughts”); resignation (“I just accepted the pain”); and distraction (“I  
distracted myself,” “I looked for support from someone”). One item will also record if “Nothing” was done to 
deal with pain.  Internal consistency reliabilities of the copi[INVESTIGATOR_901258] α=.[ADDRESS_1264164] studies. Two  
items will be added reflecting Acceptance-based strategies (as opposed to pain control–related strategies;  
Hayes et al., 1999) based on Vowles et al.(Vowles et al., 2007): “Tried to accept the pain and focus on what I was 
doing;  “Told, myself that the pain does not have to stop me.” An additional item reflects “guarding,” which is  
characteristic of somatizing, “Restrict my activity to keep from hurting myself.” Patients will also be asked to  
record an answer using free response (voice recording), to be categorized by [CONTACT_901305]. This will allow  us 
to compare free responses with categorized ones. Effectiveness of the copi[INVESTIGATOR_901259].  IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
22 of 46
Treatment: STD+MobileApp condition (i.e., painTRAINER©)
The MobileApp condition participants will engage in standard (STD) conservative dental treatment for their TMD 
pain (i.e., placement of maxillary splint; prescription of NSAIDS; prescription of soft diet; see below re 
Concomitant Treatments). However, instead of a therapi[INVESTIGATOR_541]-led psychosocial component, the STD+MobileApp 
condition will employ an online cognitive-behavioral treatment program known as painTRAINER. The 
painTRAINER program is an interactive, online tool that teaches strategies that patients can use to manage pain. 
The program was developed by [CONTACT_901306], led by [CONTACT_901307], and Frank Keefe at Duke (R01AR057346), and refined by [CONTACT_901308]. 
This program was chosen 1) because of its close correspondence to the content and session time provided in the 
STD+CBT condition; and 2) because of its current use in research, demonstrating effects on depressive 
symptoms, catastrophizing, and pain interference (Allen et al., 2021). PainTRAINER is also currently being used 
by [CONTACT_901309] (Lyn DeBar, PI: [CONTACT_62089]3AG067493). The painTRAINER 
program is made up of 8 sessions, each lasting about 45-60 minutes. It was designed so that registered 
researchers are able to access the data collected (e.g., session completion data) allowing tracking of adherence. 
Workbooks and scripts for RAs are also provided. For the purposes of this trial, the first [ADDRESS_1264165] 2 
components of the painTRAINER program will be combined, creating 6 weekly sessions of about 50-75 minutes 
each, as in the two treatment conditions currently being run in the Parent Study. An outline of the sessions for 
MobileApp treatment is in Table 2. Because painTRAINER is a general program for chronic pain, some 
modifications will be made to the overall patient program (though not to the painTRAINER program itself) to 
make it more similar to the TMD-
specific CBT program in the IATP+CBT 
condition. Specifically, in addition to 
attending to Session [ADDRESS_1264166]-led conditions.
6.1.2 ADMINISTRATION AND/OR DOSING
Administration and Dosing: Patients will be given [ADDRESS_1264167] in the Dental Clinical Research Center operatory.  Psychosocial treatment 
(painTRAINER) will be conducted remotely via mobile app. 
6.[ADDRESS_1264168]-led treatments of the parent study, painTRAINER assigns practice assignments in each module. 
IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264169] BIAS
In this feasibility trial neither randomization nor blinding of patient or research assistant is possible.  
6.4 STUDY INTERVENTION/EXPERIMENTAL MANIPULATION ADHERENCE
For this treatment, participant adherence will be measured via records from painTRAINER as to assignments 
completed. ES response rates and tasks completed for each participant will be monitored via the smartphone 
app system by [CONTACT_740546] X3 weekly. 
6.[ADDRESS_1264170] Treatment (STD). The painTRAINER program will be provided alongside a standardized version of 
conventional conservative care for patients with TMD/Orofacial pain. Standard Treatment (STD) will consist of 
splint therapy plus soft diet and oral anti-inflammatory agents (Canales et al., 2016; Stack & Stack, 1992). The 
primary rationale for this aspect of treatment is to change the oral habits of patients with respect to clenching 
and bruxing, and to provide a sufficient respi[INVESTIGATOR_901260] (despi[INVESTIGATOR_901261]). Patients will receive the intraoral splint during the first 
treatment visit, 1-[ADDRESS_1264171] continuously (except for 
eating) if possible for the succeeding 4 weeks. After 4 weeks it will be recommended to patients that they start 
to taper the splint (e.g., use only as a night guard) in preparation for discontinuing the splint altogether. The 
purpose of this is to try to prevent the patient from becoming so comfortable with the splint that he/she starts 
clenching or bruxing on the splint itself. However, we discovered in our earlier work that many patients (~50%) 
elected to retain the splint and to wear it especially as a night guard, with good results, whereas others 
discontinued the splint as recommended (also with good results). Given the good outcomes found regardless of 
duration of use of the splint, we will make the recommendation for discontinuation, but not require patients to 
stop using the splint if they feel it is useful for them. Splint use will be monitored throughout the course of the 
study, and amount of use will serve as a variable for later analysis. In addition to the splint, subjects will also be 
given a 14-day course of non-steroidal anti-inflammatory medication (NSAIDs; naproxen sodium 550 mg po BID; 
or 400-600 mg Ibuprofen TID or QID; medication and dose to be determined by [CONTACT_901310]). Extra 
strength Tylenol will be substituted for naproxen for those patients who claim to have difficulty with NSAIDs or 
who have gastric ulcer disease, kidney disease or other contraindications. A soft diet will also be prescribed with 
special attention paid to avoiding foods that require extreme jaw opening (e.g., large sandwiches) or foods that 
have caused pain in the past (e.g., steak). Patients will be asked to continue using the splint and the soft diet 
until the end of the 6-week treatment period, after which they will be informed that they may alter the 
treatment as they see fit (e.g., discontinuing the splint), but recommending care in their diet.
6.5.1 RESCUE THERAPY
For those patients, if any, whose condition deteriorates during treatment (as reported to the RAs), referrals will 
be made to other providers, either inside or outside of UConn Health. Patients for whom their splints do not fit 
correctly, or who experience discomfort with the splint,  will be seen promptly be dental staff to correct the 
issue.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
24 of 46
7 STUDY INTERVENTION/EXPERIMENTAL MANIPULATION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1 DISCONTINUATION OF STUDY INTERVENTION/EXPERIMENTAL MANIPULATION
If a subject discontinues treatment (the intervention) but remains available for the posttreatment follow-up, 
that follow-up will be completed.
If a subject is scheduled for treatment but never appears, and is unable to be reached for treatment 
rescheduling, attempts to schedule treatment will continue for a period of [ADDRESS_1264172] 
such persons for the posttreatment assessment. 
If, during the Research Assistant’s attempts to schedule the first therapy appointment, the subject says he or she 
no longer wants or are able to attend treatment, the subject will still be asked to participate in the research 
follow-up.  No further attempts to schedule treatment will be made, even if 4 weeks has not passed.
All data collection will be discontinued only if the patient expressly states that he or she wishes to discontinue 
participation entirely, at which point all communication with that person ceases.
If a clinically significant finding is identified (including, but not limited to changes from baseline in pain or 
functioning) after enrollment, the investigator or qualified designee will determine if any change in participant 
management is needed. Any new clinically relevant finding will be reported as an adverse event (AE).
 
The data to be collected at the time of study intervention discontinuation will include the following:
The reason(s) for discontinuing the participant from the intervention, and methods for determining the need 
to discontinue
If the participant is due to complete assessments within [ADDRESS_1264173] 
agreement.  
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY
The PI [INVESTIGATOR_147140] (withdraw) a participant from the study for the following reasons:
Any event or medical condition or situation occurs such that continued collection of follow-up study data 
would not be in the best interest of the participant or might require an additional treatment that would 
confound the interpretation of the study
The participant meets an exclusion criterion (either newly developed or not previously recognized) that 
precludes further study participation after being consented
The reason for participant discontinuation or withdrawal from the study will be recorded in the Treatment and 
Study Dropout database. Subjects who sign the informed consent form, and receive the study intervention, and 
subsequently withdraw, or are discontinued from the study, will not be replaced. IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264174] such persons for follow-up assessments. 
If, during the Research Assistant’s attempts to schedule the first therapy appointment, the subject says he or she 
no longer wants or is able to follow the online treatment program, the subject will still be asked to participate in 
the research follow-up.  No further attempts to schedule treatment will be made, even if the 6-week post 
randomization period has not passed.
7.[ADDRESS_1264175] be taken if a participant fails to return to respond to the Research Assistant for a 
required study visit (in person or virtual):
The site will attempt to contact [CONTACT_2299], reschedule the missed visit within a week if possible, counsel 
the participant on the importance of maintaining the assigned visit schedule and ascertain if the participant 
wishes to and/or should continue in the study
Before a participant is deemed lost to follow-up, the project director or designee will make every effort to 
regain contact [CONTACT_6635] (where possible, 3 or more telephone calls., e-mails and/or texts, and, if 
necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). 
These contact [CONTACT_9145]’s study file.
Should the participant continue to be unreachable, he or she will be considered to be lost to follow-up.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
26 of 46
8 STUDY ASSESSMENTS AND PROCEDURES
8.1 ENDPOINT AND OTHER NON-SAFETY ASSESSMENTS
Baseline session - Diagnostic Evaluation (DE). Persons meeting initial eligibility criteria will be consented and 
scheduled for a baseline diagnostic evaluation session. At this session baseline questionnaires will be completed 
remotely by [CONTACT_901311], with assistance from a RA by [CONTACT_756] (see Table 1 above) 
and/or WebEx conference (see Table 1 above).  At an in-person clinical examination potential participants will 
be examined by [CONTACT_901312] (DC/TMD). Following this 
examination prospective subjects will have a panoramic X-ray taken to rule out gross arthritic or anatomic 
damage to the TM joint. 
Posttreatment Data Collection. At the data at which the patient should have completed 6 weeks of treatment 
the Patient will be asked to complete follow-versions of the dependent measures, including the pain 
assessments, and the process measures. This will be done remotely via REDCap surveys. At this point, patients 
will once again be asked to participate in ES via MetricWire for 7 days to determine if situation-specific copi[INVESTIGATOR_901262]. $[ADDRESS_1264176]-Tx data collection + up to $40 for Experience Sampling for 
1 wk.
8.2 SAFETY ASSESSMENTS
Patient pain and functioning, along with medication usage and adherence to splint and soft diet, will be assessed 
at every follow-up visit by [CONTACT_3647], using data collection forms for this purpose. Any patient reports of pain 
or functioning problems will be reported to the Principal Investigator [INVESTIGATOR_901263]/dental follow-up. 
8.[ADDRESS_1264177] medical occurrence that presents during the course of a clinical investigation that might be 
caused by [CONTACT_901313]. 
Adverse events are categorized into those that are expected (predictable) and those that are unexpected 
(unpredictable). An adverse event is considered an unanticipated problem involving risk to subjects or others 
only when the event is unexpected (see definition below), related or possibly related to the research 
intervention (see definition below), and places the subjects or others at greater risk of harm than was previously 
recognized.
8.3.[ADDRESS_1264178] one of the following criteria:
• Death
• Life-threatening
• Hospi[INVESTIGATOR_059]/prolongation of existing hospi[INVESTIGATOR_901264]: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
27 of 46
• Congenital anomaly/birth defect
• Persistent or significant disability/incapacity
• An important medical event that, based upon appropriate medical judgment, requires medical or surgical 
intervention to prevent one of the outcomes listed above.
A non-serious adverse event is any undesirable symptom or occurrence a subject experiences during 
participation in a clinical trial that does not meet the criteria for serious.
8.3.3 CLASSIFICATION OF AN ADVERSE EVENT
[IP_ADDRESS] SEVERITY OF EVENT
For adverse events (AEs) not included in the protocol defined grading system, the following guidelines will be 
used to describe severity.
Mild: Events require minimal or no treatment and do not interfere with the participant's daily activities.
Moderate: Events result in a low level of inconvenience or concern with the therapeutic measures. 
Moderate events may cause some interference with functioning.
Severe: Events interrupt a participant's usual daily activity and may require systemic drug therapy or other 
treatment. Severe events are usually potentially life-threatening or incapacitating. Of note, the term 
"severe" does not necessarily equate to "serious".
[IP_ADDRESS] RELATIONSHIP TO STUDY INTERVENTION/EXPERIMENTAL MANIPULATION
All adverse events (AEs) will have their relationship to study procedures, including the intervention, assessed by 
[CONTACT_9152]-trained clinician based on temporal relationship and his/her clinical judgment. The degree of 
certainty about causality will be graded using the categories below.
Related: The AE is known to occur with the study procedures, there is a reasonable possibility that the 
study procedures caused the AE, or there is a temporal relationship between the study procedures and 
the event. Reasonable possibility means that there is evidence to suggest a causal relationship between 
the study procedures and the AE.
Not Related: There is not a reasonable possibility that the study procedures caused the event, there is 
no temporal relationship between the study procedures and event onset, or an alternate etiology has 
been established.
 
[IP_ADDRESS] EXPECTEDNESS
A clinician with appropriate expertise will be responsible for determining whether an adverse event (AE) is 
expected or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the event 
is not consistent with the risk information previously described for the study procedures.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
28 of 46
Expected AEs are defined as an event that is anticipated on the basis of prior experience with the intervention 
under investigation or with related interventions; an event identified in the Investigator’s Brochure and/or study 
drug labels for post marketing studies; an event that is likely due to the underlying condition of the patient being 
studied; or an event attributed to the patient population being studied. Such events do not require reporting to 
the IRB (unless the nature, severity or frequency of the events is different/greater than previously anticipated) 
but may require reporting to the sponsor based on terms of the clinical trial agreement and/or protocol.
Unexpected AEs include any untoward medical occurrence not listed in the protocol and the informed consent 
document and not anticipated on the basis of prior experience with the intervention under investigation or with 
related interventions; an event that cannot be attributed to the underlying condition of the patient being 
studied or to the patient population; or expected events with frequency
and/or severity exceeding what was anticipated. 
8.3.4 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of study 
personnel during study visits and interviews of a study participant presenting for care, or upon review by a study 
monitor.
All AEs, not otherwise precluded per the protocol, will be captured in the Adverse Events database. Information 
to be collected includes event description, time of onset, RA, assessment of severity, relationship to study 
procedures (assessed only by [CONTACT_8703] a diagnosis), and disposition of the 
event. All AEs occurring while on study will be documented appropriately regardless of relationship. All AEs will 
be followed to adequate resolution.
Any medical or psychiatric condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant's condition deteriorates at 
any time during the study, it will be recorded as an AE.
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each 
level of severity to be performed. Documentation of onset and duration of each epi[INVESTIGATOR_901265].
The project director or other trained staff will record events with start dates occurring any time after informed 
consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation. At 
each study status meeting the investigator will inquire about the occurrence of AE/SAEs since the last meeting. 
Events will be followed for outcome information until resolution or stabilization. 
8.3.[ADDRESS_1264179] 
(IRB) as soon as possible, but in no event later than [ADDRESS_1264180] learns of the 
event. 
Any AE meeting the specified Serious Adverse Event criteria will be submitted on an SAE form to NIDCR’s 
centralized safety system via Rho Product Safety. This report may be sent by [CONTACT_40743]. Once submitted, Rho IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264181] Information:
Product Safety Fax Line (US):  [PHONE_286]
Product Safety Fax Line (International):  [PHONE_287]
Product Safety Email:  [EMAIL_305] 
General questions about SAE reporting can be directed to the Rho Product Safety Help Line (available 8:00AM – 
5:00PM Eastern Time):  
US:  [PHONE_288]
International: [PHONE_289]
The study’s clinically responsible individual will complete a Serious Adverse Event Form and submit via fax or 
email within the following timelines:  
All deaths and immediately life-threatening events, whether related or unrelated, will be recorded on the 
Serious Adverse Event Form and submitted to Product Safety within [ADDRESS_1264182]
NA
8.3.9 REPORTING OF PREGNANCY
In the case of a participant reporting pregnancy, the PI [INVESTIGATOR_901266]. If the participant has completed treatment and is no longer taking study medication the participant will 
likely continue in the study. Given the demographics of this pain problem pregnancies are not very likely.
8.4 UNANTICIPATED PROBLEMS
8.4.1 DEFINITION OF UNANTICIPATED PROBLEMS (UP)
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to subjects 
or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
30 of 46
Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described 
in the protocol-related documents, such as the Institutional Review Board (IRB)-approved research protocol 
and informed consent document; and (b) the characteristics of the participant population being studied;
Related or possibly related to participation in the research ("possibly related" means there is a reasonable 
possibility that the incident, experience, or outcome may have been caused by [CONTACT_226592]); and
Suggests that the research places participants or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.
8.4.2 UNANTICIPATED PROBLEMS REPORTING
The investigator will report unanticipated problems (UPs) to the reviewing Institutional Review Board (IRB). The 
UP report will include the following information:
Protocol identifying information: protocol title and number, PI's name, and the IRB project number
A detailed description of the event, incident, experience, or outcome
An explanation of the basis for determining that the event, incident, experience, or outcome represents an 
UP
A description of any changes to the protocol or other corrective actions that have been taken or are 
proposed in response to the UP
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:
UPs that are serious adverse events (SAEs) will be reported to the IRB and to the funding agency within 24 
hours of the investigator becoming aware of the event
Any other UP will be reported to the IRB and to the funding agency within 5 days of the investigator 
becoming aware of the problem
All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]'s written 
reporting procedures), the supporting agency head (or designee), and the Office for Human Research 
Protections (OHRP) within 5 days of the IRB's receipt of the report of the problem from the investigator
All unanticipated problems will be reported to NIDCR concurrently with reporting to the IRB. These reports will 
be made to NIDCR’s centralized reporting system via Rho Product Safety:
Product Safety Fax Line (US):  [PHONE_286]
Product Safety Fax Line (International):  [PHONE_287]
Product Safety Email:  [EMAIL_305] 
General questions about UP reporting can be directed to the Rho Product Safety Help Line (available 8:00AM – 
5:00PM Eastern Time):  
US:  [PHONE_288]
International: [PHONE_289]
8.4.[ADDRESS_1264183] the 
participant to discuss options for that person to continue with the study or to seek additional or alternative 
treatment if necessary and appropriate.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
31 of 46IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
32 of 46
9 STATISTICAL CONSIDERATIONS
9.1 STATISTICAL HYPOTHESES
Primary Endpoints:
oFeasibility: Recruitment of 20 patients in 12 months who agree to participate in a mobile app only 
treatment condition
oAcceptability: Treatment Acceptability and Adherence Scale scores
oAdherence to Treatment: Sessions completed; Between session assignments completed.
Secondary Efficacy Endpoint(s): 
oPain (0-10: The average of ratings of current pain, average pain, and worst pain during the week on 
the Graded Chronic Pain Scale)
oDepression Symptoms (0-60: score on the CES-D)
oInterference with functioning (0-60: score on the MPI [INVESTIGATOR_546328]); (0-200 on the Jaw 
Functional Limitation Scale)
Tertiary Endpoint(s);
oCopi[INVESTIGATOR_901267] (0-203, total score on the Brief Pain Copi[INVESTIGATOR_183703])
oSelf-Efficacy (0-80 on the Facial Pain Self-Efficacy Scale)
oMomentary copi[INVESTIGATOR_901268] (per Experience Sampling)
Other Tertiary/Exploratory Endpoints: Somatization; Catastrophization;
9.[ADDRESS_1264184] part these are
subjective standards. However, 20 additional participants recruited in 44 weeks (i.e., allowing for all to have 6
weeks of treatment plus a follow-up) will be sufficient to establish our ability to recruit for this type of
intervention. Likewise, we expect to retain at least 80% at posttreatment within a 95% confidence interval of +/-
20%. (In actuality, our typi[INVESTIGATOR_901269]: 87+% at post). This number of patients will
also be sufficient to establish equivalence of credibility between the MobileApp and the two therapi[INVESTIGATOR_541]-led
treatments (hypothesis 1).
The test of credibility was based on a two-group design, such that the MobileApp condition is compared to a
group comprised of patients from the other two treatment conditions. Specifically, power was ascertained
based on a test of equivalence between the MobileApp condition and the therapi[INVESTIGATOR_541]-led conditions on treatment
credibility, based on between-treatment credibility data provided by [CONTACT_901314]. (Arch et al., 2012). An
equivalence test of means using two one-sided equal-variance t-tests with equivalence limits of -2.5 and 2.5,
an actual difference between the means = 1.1, and a standard deviation = 1.7, would require sample sizes of
19 in each group to achieve 81% power at a 5.0% significance level. (Analysis based on output from Pass
2019).IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
33 of 46
9.3 POPULATIONS FOR ANALYSES
Intention-to-Treat (ITT) Analysis Population (i.e., all participants assigned to treatment)
9.4 STATISTICAL ANALYSES
9.4.1 GENERAL APPROACH
 
Acceptability will be assumed if 80% of patients assigned to treatment agree to participate in the 
painTRAINER program.
Acceptability and Credibility scores will be compared with published norms. 
Credibility/expectancy (CEQ) scores will also be compared to those from the two parent study 
conditions, using a non-superiority analysis.  
Adequate Adherence will be declared if patients complete 80% of planned assignments
9.4.2 ANALYSIS OF THE PRIMARY ENDPOINT(S)
H1: The mobile application (painTrainer) will prove to be a feasible and acceptable intervention.
[ADDRESS_1264185] 80% of patients to
complete at least 3 of the 6 planned modules. No additional analysis is planned for this hypothesis.
H2a. The mobile application (painTrainer) will prove to be a credible treatment. Scores on the treatment 
credibility measure (the treatment credibility/expectancy questionnaire; CEQ) will be computed for the 
MobileApp patients and compared to means published by [CONTACT_901315], (Devilly & Borkovec, 2000). 
Scores like those in the general range (i.e., within 2 SD) of those reported by [CONTACT_901316]+MobileApp condition is credible. 
H2b: The mobile application (painTrainer) will prove to be as credible as the therapi[INVESTIGATOR_541]-led treatments currently 
provided in the Parent study, as demonstrated by [CONTACT_901293]-inferiority on credibility scores. Tests for 
equivalence of means will be conducted on the posttreatment mean scores for the CRE from the MobileApp 
patients (n=20) and from the two therapi[INVESTIGATOR_541]-led conditions (n=20 total). The Equivalence Tests for Differences 
Between Two Independent Means, or the Two One-Sided Test (TOST) procedure, entails performing two one-
sided tests to examine whether the observed data are surprisingly larger than an equivalence boundary lower 
than zero (ΔL) or surprisingly smaller than an equivalence boundary larger than zero (ΔU) (Schuirmann, 1987). In 
this case the symmetric range of -2.5 to 2.5 is based on differences observed by [CONTACT_901314]. (Arch et al., 2012). If 
both tests fail to show significant differences between the MobileApp and the combined means of the two 
therapi[INVESTIGATOR_541]-led conditions then we may claim that the CEQ means are “equivalent” (though we may not declare
the conditions “the same”). That is, failure to find mean between-group differences on credibility, given these 
constraints, would suggest equivalence of means on this measure. 
H3. Patients in the MobileApp will show acceptable adherence to the scheduled procedures, as evidenced by
[CONTACT_901292] a treatment adherence measure, and through completion of sessions (> 3 of 6 planned modules) and 
exercises monitored by [CONTACT_901317] (i.e., > 80% completion of recommended exercises), as well 
as those exercises administered and monitored by [CONTACT_740546] (>80% of worksheet and other exercise completion).IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
34 of 46
RESEARCH STRATEGY
9.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)
Analysis of Secondary endpoints will entail comparisons of secondary and tertiary endpoint variables from this 
study with the same variables from the conditions in the parent study, using t-tests and univariate ANOVA. Due 
to the small N of this study, these analyses will not be cited as evidence of differences (or lack of differences) 
between this intervention and the therapi[INVESTIGATOR_541]-led interventions. 
 
9.4.4 SAFETY ANALYSES
Pain will be tracked at every treatment (by [CONTACT_901318]) and follow-up visit. Adverse and Serious 
Adverse events will be tracked to determine whether online treatment yields an unusual number of such events.
9.4.[ADDRESS_1264186] of dispositional moderators such as somatization, 
catastrophization, acceptance and neuroticism on pain and adherence. Another analysis will separate those 
whose pain is extremely variable from those whose pain is stable at pretreatment to determine if these 
represent different types of patients.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
35 of 46
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS
10.1.1 INFORMED CONSENT PROCESS
Consent forms describing in detail the study intervention, study procedures, and risks are given to the 
participant, and documentation of informed consent is required prior to starting intervention/administering 
study intervention.  
[IP_ADDRESS] CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS
*Consent Form
*HIPAA form
*These will be administered remotely. Potential participants will have access to forms via links to REDCap. 
Electronic signatures will be logged and saved. 
[IP_ADDRESS] CONSENT PROCEDURES AND DOCUMENTATION
Recruitment and screening. Patients will be recruited both through the University dental clinics and through 
newspaper, radio and internet advertisements. Persons will respond to the advertisement by [CONTACT_756]. Those 
who call will be told that the purpose of the project is to test different TMD treatments. Those interested will be 
screened over the telephone for basic inclusion/exclusion criteria.  Those who meet eligibility at this point will 
be scheduled within 14 days for a diagnostic evaluation (DE). Persons meeting initial eligibility will come to the 
Health Center for the DE. 
Consent Process. Prior to any activities the person will be administered the Consent Form, and the project will 
again be described. The consent process will be conducted by [CONTACT_19908] (RA) by [CONTACT_756]. This 
phone call will either be conducted immediately after the prospective participant passes the Quick Screen, or at 
a later time arranged between the person and the RA. The consent form will be sent to the prospective 
participant via REDCap link sent by e-mail. While on the telephone the RA will assist the prospective participant 
with opening the REDCap link and will stand by [CONTACT_901319], and will explain any 
parts of the Consent Form about which the person has questions. Those who then still agree to participate will 
be asked to sign the Consent Form. Study procedures will not proceed until a copy of the consent, electronically 
signed by [CONTACT_901320], have been merged and a signed copy returned via e-mail to 
the participant
10.1.2 STUDY DISCONTINUATION AND CLOSURE
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. 
Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_224965], investigators, UConn Health Research Administration, 
UCH IRB, and the funding agency. If the study is prematurely terminated or suspended, the Principal Investigator 
(PI) will promptly inform study participants, the IRB, and sponsor and will provide the reason(s) for the 
termination or suspension. Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to 
study visit schedule.
Circumstances that may warrant termination or suspension include, but are not limited to:
Determination of unexpected, significant, or unacceptable risk to participantsIRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
36 of 46
Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]
Insufficient compliance of study staff to the protocol (i.e., significant protocol violations)
Data that are not sufficiently complete and/or evaluable
Determination of futility
The study may resume once concerns about safety, protocol compliance, and data quality are addressed, and 
satisfy the funding agency, sponsor, IRB, or other relevant regulatory or oversight bodies (OHRP, DSMB).
10.1.[ADDRESS_1264187] party without prior written approval of the sponsor/funding agency.
 
All research activities will be conducted in as private a setting as possible.
The study monitor, other authorized representatives of the sponsor, and representatives of the Institutional 
Review Board (IRB), may inspect all documents and records required to be maintained by [CONTACT_093], 
including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the 
participants in this study. The clinical study site, UConn Health, will permit access to such records.
 
The study participant’s contact [CONTACT_9168]. At the end 
of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_54455], Institutional policies, or sponsor requirements.
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be 
transmitted to and stored at an appropriate national Data Coordinating Center. This information will not include 
the participant’s contact [CONTACT_1290]. Rather, individual participants and their research data will 
be identified by a unique study identification number. The study data entry and study management systems 
used by [CONTACT_901321]. 
At the end of the study, all study databases will be de-identified and archived at the Data Coordinating Center.
 
Measures Taken to Ensure Confidentiality of Data Shared per the NIH Data Sharing Policies. It is NIH policy that 
the results and accomplishments of the activities that it funds should be made available to the public (see 
https://grants.nih.gov/policy/sharing.htm). The PI [INVESTIGATOR_901270], confidentiality, and security for data dissemination 
and reuse (e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant). 
Plans for archiving and long-term preservation of the data will be implemented, as appropriate.
10.1.4 FUTURE USE OF STORED SPECIMENS AND DATA
Data collected for this study will be analyzed and stored at the UConn Health General Clinical Research Center. 
When the study is completed, access to study data and/or samples will be provided through UConn Health 
General Clinical Research Center. Those wishing access to the data will apply to the Principal Investigator, who 
will authorize access to qualified investigators with legitimate scientific questions. IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
37 of 46
10.1.5 KEY ROLES AND STUDY GOVERNANCE
Principal Investigator [INVESTIGATOR_901271] D. Litt, PhD Professor and Principal 
Investigator[INVESTIGATOR_901272], Department of Oral 
Diagnosis 
UConn School of Dental Medicine UConn School of Dental Medicine
Division of Behavioral Sciences & Community 
HealthDivision of Oral and Maxillofacial Surgery
[PHONE_18686] [PHONE_18687]
[EMAIL_17188] [EMAIL_17189]
 
10.1.6 SAFETY OVERSIGHT
In addition to the PI’s responsibility for oversight, study oversight will be under the direction of a Data and 
Safety Monitoring Board, which will meet at least annually throughout the course of the study.
10.1.[ADDRESS_1264188] of the trial is 
in compliance with the currently approved protocol, with International Council on Harmonization Good Clinical 
Practice (ICH GCP) guidelines, and with applicable regulatory requirements.
Monitoring activities will be as follows:
Research Assistants or the clinical coordinator (throughout the study), will monitor patient pain, behaviors 
and complaints. Monitoring will be at least weekly during the treatment phase, and at the posttreatment 
follow-up. Any indication of patient safety being at issue will be immediately reported to the PI [INVESTIGATOR_901273].
Independent audits may be conducted by [CONTACT_901322].
NIDCR and its designees will conduct regular clinical monitoring.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264189], data collection, documentation and 
completion. We will follow a common quality management plan.
Quality control (QC) procedures will be implemented as follows:
Informed consent - Study staff will review both the documentation of the consenting process as well as a 
percentage of the completed consent documents. This review will evaluate compliance with GCP, accuracy, and 
completeness. Feedback will be provided to the study team to ensure proper consenting procedures are 
followed.
Source documents and the electronic data - Data will be initially captured on source documents (see Section 
10.1.9, Data Handling and Record Keepi[INVESTIGATOR_007]) and will ultimately be entered into the study database using REDCAP. 
To ensure accuracy site staff will compare a representative sample of source data against the database, 
targeting key data points in that review.
Intervention Fidelity - Consistent delivery of the study interventions will be monitored throughout the 
intervention phase of the study. Procedures for ensuring fidelity of intervention delivery are described in Section 
6.2.1, Interventionist Training and Tracking.
Protocol Deviations - The study team will review protocol deviations on an ongoing basis and will implement 
corrective actions when the quantity or nature of deviations are deemed to be at a level of concern. Any 
protocol deviation caused by [CONTACT_901323].
Should independent monitoring become necessary, the PI [INVESTIGATOR_9115], 
source data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456]/funding agency, 
and inspection by [CONTACT_3482], in this case, UCH IRB.
10.1.[ADDRESS_1264190] KEEPI[INVESTIGATOR_1645]
[IP_ADDRESS] DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES
Data collection will be the responsibility of the clinical trial staff under the supervision of the Principal 
Investigator. The Principal Investigator [INVESTIGATOR_391316], completeness, legibility, 
and timeliness of the data reported.
All source documents will be completed in a neat, legible manner to ensure accurate interpretation of data.
When necessary, hard copi[INVESTIGATOR_901274]/enrolled in the study. Data recorded in the 
electronic case report form (eCRF) derived from source documents will be consistent with the data recorded on 
the source documents. All other patient reports will be entered directly in the REDCAP system.
Clinical data (including AEs) will be entered into a tracking database. The data system includes password 
protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate. Clinical data will be entered directly from the source documents and/or from patient 
reports.IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
39 of 46
[IP_ADDRESS] STUDY RECORDS RETENTION
Study documents will be retained for a minimum of [ADDRESS_1264191] follow-up has been recorded. These 
documents should be retained for a longer period, however, if required by [CONTACT_427]. No records will be 
destroyed without the written consent of the sponsor/funding agency, if applicable. It is the responsibility of the 
sponsor/funding agency to inform the investigator when these documents no longer need to be retained.
10.1.10 PROTOCOL DEVIATIONS
This protocol defines a protocol deviation as any noncompliance with the clinical trial protocol, International 
Council on Harmonization Good Clinical Practice (ICH GCP), or Manual of Procedures (MOP) requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result 
of deviations, corrective actions will be developed by [CONTACT_3483].
These practices are consistent with ICH GCP:
Section 4.5 Compliance with Protocol, subsections 4.5.1, 4.5.2, and 4.5.3
Section 5.1 Quality Assurance and Quality Control, subsection 5.1.1
Section 5.20 Noncompliance, subsections 5.20.1, and 5.20.2.
It will be the responsibility of the Principal Investigator [INVESTIGATOR_901275].  All deviations will be recorded in the study tracking database within 2 days of study staff becoming 
aware of them, and reported to the UCH IRB and to NIDCR on an annual basis. The process for identifying 
protocol deviations is described in detail in a separate Data Quality Monitoring Plan. 
10.1.11 PUBLICATION AND DATA SHARING POLICY
This study will be conducted in accordance with the following publication and data sharing policies and 
regulations:
National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the 
published results of NIH funded research. It requires scientists to submit final peer-reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for 
publication.
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As 
such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-
reviewed journals. Data from this study may be requested from other researchers [ADDRESS_1264192].IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264193] Treatment
UP Unanticipated Problem
US [LOCATION_002]IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
41 of 46
10.4 PROTOCOL AMENDMENT HISTORY
Version Date Description of Change Brief Rationale
    
    
    
    
    
    
    
    
    
    
    
    
    
    IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
42 of 46
11 REFERENCES
Aggarwal, V. R., Tickle, M., Javidi, H., & Peters, S. (2010). Reviewing the evidence: can cognitive behavioral 
therapy improve outcomes for patients with chronic orofacial pain? Journal of Orofacial Pain, 24(2), 163-
171. http://www.ncbi.nlm.nih.gov/pubmed/20401354 
Allen, K. D., Beauchamp, T., Rini, C., Keefe, F. J., Bennell, K. L., Cleveland, R. J., Grimm, K., Huffman, K., Hu, D. G., 
Santana, A., Saxena Beem, S., Walker, J., & Sheikh, S. Z. (2021). Pi[INVESTIGATOR_794587]-based pain 
copi[INVESTIGATOR_901276]. BMC Rheumatology, 5(1), 
20. https://doi.org/10.1186/s41927-021-[ZIP_CODE]-6 
Arch, J. J., Eifert, G. H., Davies, C., Plumb Vilardaga, J. C., Rose, R. D., & Craske, M. G. (2012). Randomized clinical 
trial of cognitive behavioral therapy (CBT) versus acceptance and commitment therapy (ACT) for mixed 
anxiety disorders. Journal of Consulting and Clinical Psychology, 80(5), 750-765. 
https://doi.org/10.1037/a0028310 
Association, A. P. (2013). DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure—Adult. American 
Psychiatric Association. 
Barta, W. D., Tennen, H., & Litt, M. (2011). Measurement reactivity in diary research. In M. M. Mehl & T. S. 
Conner (Eds.), Handbook of research methods for studying daily life (pp. 108-123). Guilford Press. 
Bhatia, A., Kara, J., Janmohamed, T., Prabhu, A., Lebovic, G., Katz, J., & Clarke, H. (2021). User Engagement and 
Clinical Impact of the Manage My Pain App in Patients With Chronic Pain: A Real-World, Multi-site Trial 
[Original Paper]. JMIR Mhealth Uhealth, 9(3), e26528. https://doi.org/10.2196/[ZIP_CODE] 
Burns, J. W. (2016). Mechanisms, mechanisms, mechanisms: it really does all boil down to mechanisms. Pain, 
157(11), 2393-2394. https://doi.org/10.1097/j.pain.0000000000000696 
Burns, J. W., Van Dyke, B. P., Newman, A. K., Morais, C. A., & Thorn, B. E. (2020). Cognitive behavioral therapy 
(CBT) and pain education for people with chronic pain: Tests of treatment mechanisms. Journal of 
Consulting and Clinical Psychology, 88(11), 1008-1018. https://doi.org/10.1037/ccp0000612 
Canales, G. d. l. T., Manfredini, D., Grillo , C. M., Guarda-Nardini, L., Gonçalves, L. M., & Rizzatti Barbosa, C. M. 
(2016). Therapeutic effectiveness of a combined counseling plus stabilization appliance treatment for 
myofascial pain of the jaw muscles: A pi[INVESTIGATOR_799]. Cranio. https://doi.org/DOI: 
10.1080/08869634.2016.1168071 
Cosio, D. (2016). A review of the common factors model and its application in pain management. International 
Journal of Complementary and Alternative Medicine, 3(2), 48-58. 
https://doi.org/10.[ZIP_CODE]/ijcam.2016.03.[ZIP_CODE] 
Devilly, G. J., & Borkovec, T. D. (2000). Psychometric properties of the credibility/expectancy questionnaire. 
Journal of Behavior Therapy and Experimental Psychiatry, 31(2), 73-86. https://doi.org/10.1016/s0005-
7916(00)[ZIP_CODE]-4 
Dworkin, S. F., & LeResche, L. (1992). Research diagnostic criteria for temporomandibular disorders: review, 
criteria, examinations and specifications, critique. Journal of Craniomandibular Disorders, 6(4), 301-355. 
Dworkin, S. F., & Massoth, D. L. (1994). Temporomandibular disorders and chronic pain: disease or illness? 
Journal of Prosthetic Dentistry, 72(1), 29-38. https://doi.org/0022-3913(94)[ZIP_CODE]-5 [pii] 
Eaton, W. W., Muntaner, C., Smith, C., Tien, A., & Ybarra, M. (2004). Center for Epi[INVESTIGATOR_260994]: Review and revision (CESD and CESD-R). In M. E. Maruish (Ed.), The Use of Psychological Testing 
for Treatment Planning and Outcomes Assessment (3rd ed., pp. 363-377). Lawrence Erlbaum. 
Ehde, D. M., Dillworth, T. M., & Turner, J. A. (2014). Cognitive-behavioral therapy for individuals with chronic 
pain: efficacy, innovations, and directions for research. American Psychologist, 69(2), 153-166. 
https://doi.org/10.1037/a0035747 
Finsrud, I., Nissen-Lie, H. A., Vrabel, K., Høstmælingen, A., Wampold, B. E., & Ulvenes, P. G. (2022). It's the 
therapi[INVESTIGATOR_901277]: The structure of common therapeutic relationship factors. Psychotherapy 
Research, 32(2), 139-150. https://doi.org/10.1080/10503307.2021.1916640 IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
[ADDRESS_1264194], M. B., Williams, J. B. W., Karg, R. S., & Spi[INVESTIGATOR_626], R. L. (2015). Structured Clinical Interview for DSM-5 Disorders 
- Research Version  (SCID-5-RV, AUG 2014 FINAL). American Psychiatric Publishing, Inc.  . 
Flor, H., & Turk, D. C. (2011). Chronic pain: an integrated biobehavioral approach. IASP Press. 
Garfield, S. L. (1995). Psychotherapy: An eclectic-integrative approach (2nd ed.). Wiley. 
Gupta, R., Luthra, R. P., Kaur, D., & Aggarwal, B. (2019). Temporomandibular disorders: A review. International 
Journal of Advanced Scientific Research, 4(2), 22-26. 
Häggman-Henrikson, B., Bechara, C., Pi[INVESTIGATOR_901278], B., Visscher, C. M., & Ekberg, E. (2020). Impact of Catastrophizing 
in Patients with Temporomandibular Disorders-A Systematic Review. J Oral Facial Pain Headache, 34(4), 
379-397. https://doi.org/10.[ZIP_CODE]/ofph.2637 
Harper, D. E., Schrepf, A., & Clauw, D. J. (2016). Pain Mechanisms and Centralized Pain in Temporomandibular 
Disorders. Journal of Dental Research, 95(10), 1102-1108. https://doi.org/10.1177/0022034516657070 
Hayes, S. C., Strosahl, K., & Wilson, K. G. (1999). Acceptance and commitment therapy: An experiential approach 
to behavior change. The Guilford Press. 
Haythornthwaite, J. A. (2010). IMMPACT recommendations for clinical trials: opportunities for the RDC/TMD. 
Journal of Oral Rehabilitation, 37(10), 799-806. https://doi.org/10.1111/j.1365-2842.2010.[ZIP_CODE].x 
Horvath, A. O., & Greenberg, L. (1986). The development of the Working Alliance Inventory: A research 
handbook. In L. Greenberg & W. Pi[INVESTIGATOR_901279] (Eds.), Psychotherapeutic Processes: A Research Handbook. 
Guilford Press. 
Hubble, M., Duncan, B., & Miller, S. (1999). The heart and soul of change: What works in therapy. American 
Psychological Association. 
Hurst, H., & Bolton, J. (2004). Assessing the clinical significance of change scores recorded on subjective 
outcome measures. Journal of Manipulative and Physiological Therapeutics, 27(1), 26-35. 
https://doi.org/10.1016/j.jmpt.2003.11.003 S0161475403001829 [pii] 
Imel, Z. E., & Wampold, B. E. (2008). The importance of treatment and the science of common factors in 
psychotherapy. In S. D. Brown & R. W. Lent (Eds.), Handbook of counseling psychology (4 ed., pp. 249-
266). Wiley. 
Irvine, A. B., Russell, H., Manocchia, M., Mino, D. E., Cox Glassen, T., Morgan, R., Gau, J. M., Birney, A. J., & Ary, 
D. V. (2015). Mobile-Web App to Self-Manage Low Back Pain: Randomized Controlled Trial [Original 
Paper]. J Med Internet Res, 17(1), e1. https://doi.org/10.2196/jmir.3130 
Jensen, M. P., Turner, J. A., & Romano, J. M. (1991). Self-efficacy and outcome expectancies: relationship to 
chronic pain copi[INVESTIGATOR_152295]. Pain, 44(3), 263-269. 
http://www.ncbi.nlm.nih.gov/pubmed/2052395 
Kerns, R. D., Turk, D. C., & Rudy, T. E. (1985). The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). 
Pain, 23(4), 345-356. 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=4
088697 
Kroenke, K., Spi[INVESTIGATOR_626], R. L., & Williams, J. B. (2002). The PHQ-15: validity of a new measure for evaluating the 
severity of somatic symptoms [Research Support, Non-U.S. Gov't]. Psychosomatic Medicine, 64(2), 258-
266. http://www.ncbi.nlm.nih.gov/pubmed/11914441 
Larsen, R. J., & Diener, E. (1992). Promises and problems with the circumplex model of emotion. In M. S. Clark 
(Ed.), Emotion (Vol. 13, pp. 25-29). Sage Publications. 
Litt, M. D., Shafer, D., & Napolitano, C. (2004). Momentary mood and copi[INVESTIGATOR_901280]. Health 
Psychology, 23(4), 354-362. 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1
5264971 
Litt, M. D., Shafer, D. M., Ibanez, C. R., Kreutzer, D. L., & Tawfik-Yonkers. (2009). Momentary pain and copi[INVESTIGATOR_901281]: Exploring mechanisms of cognitive behavioral treatment for chronic 
pain. Pain, 145, 160-168. IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
44 of 46
Litt, M. D., Shafer, D. M., & Kreutzer, D. L. (2010). Brief cognitive-behavioral treatment for TMD pain: long-term 
outcomes and moderators of treatment. Pain, 151(1), 110-116. https://doi.org/S0304-3959(10)[ZIP_CODE]-0 
[pii]  10.1016/j.pain.2010.06.030 
Martin, C. L., Bakker, C. J., Breth, M. S., Gao, G., Lee, K., Lee, M. A., Tiase, V. L., Tunby, L. J., Wyatt, T. H., & 
Janeway, L. M. (2021). The efficacy of mobile health interventions used to manage acute or chronic pain: 
A systematic review. Research in Nursing and Health, 44(1), 111-128. 
https://doi.org/https://doi.org/10.1002/nur.[ZIP_CODE] 
McCracken, L. M., Eccleston, C., & Bell, L. (2005). Clinical assessment of behavioral copi[INVESTIGATOR_25133]: preliminary 
results from a brief inventory. Eur J Pain, 9(1), 69-78. https://doi.org/10.1016/j.ejpain.2004.04.005 
Melzack, R. (1987). The short-form McGill Pain Questionnaire. Pain, 30(2), 191-197. https://doi.org/0304-
3959(87)[ZIP_CODE]-8 [pii] 
Milosevic, I., Levy, H. C., Alcolado, G. M., & Radomsky, A. S. (2015). The Treatment Acceptability/Adherence 
Scale: Moving Beyond the Assessment of Treatment Effectiveness. Cogn Behav Ther, 44(6), 456-469. 
https://doi.org/10.1080/16506073.2015.[ADDRESS_1264195], T., & Dworkin, S. (2008). Preliminary development and validation of the Jaw 
Functional Limitation Scale. Community Dentistry and  Oral Epi[INVESTIGATOR_623], 36(3), 228-236. 
https://doi.org/COM397 [pii]  10.1111/j.1600-0528.2007.[ZIP_CODE].x 
Ohrbach, R., Markiewicz, M. R., & McCall, W. D., Jr. (2008). Waking-state oral parafunctional behaviors: 
specificity and validity as assessed by [CONTACT_42623]. European Journal of Oral Sciences, 116, 438-
444. 
Ohrbach R. (Editor). (Version 15May2016). Diagnostic Criteria for Temporomandibular Disorders: Assessment 
Instruments. Retrieved March 15, 2016, from www.rdc-tmdinternational.org, July 15, [ADDRESS_1264196], D., Varatharajan, 
S., Mior, S., Stupar, M., Shearer, H. M., Jacobs, C., & Taylor-Vaisey, A. (2016). The Effectiveness of 
Noninvasive Interventions for Temporomandibular Disorders. The Clinical Journal of Pain, 32(3), 260-
278. https://doi.org/10.1097/AJP.0000000000000247 
Rosenstiel, A. K., & Keefe, F. J. (1983). The use of copi[INVESTIGATOR_100778]: relationship 
to patient characteristics and current adjustment. Pain, 17(1), 33-44. https://doi.org/0304-
3959(83)[ZIP_CODE]-2 [pii] 
Russell, J. A. (1980). A circumplex model of affect. Journal of Personality and Social Psychology, 39, 1161-1178. 
Schiffman, E., Ohrbach, R., Truelove, E., Look, J., Anderson, G., Goulet, J. P., List, T., Svensson, P., Gonzalez, Y., 
Lobbezoo, F., Michelotti, A., Brooks, S. L., Ceusters, W., Drangsholt, M., Ettlin, D., Gaul, C., Goldberg, L. 
J., Haythornthwaite, J. A., Hollender, L., Jensen, R., John, M. T., De Laat, A., de Leeuw, R., Maixner, W., 
van der Meulen, M., Murray, G. M., Nixdorf, D. R., Palla, S., Petersson, A., Pi[INVESTIGATOR_100777], P., Smith, B., 
Visscher, C. M., Zakrzewska, J., Dworkin, S. F., International Rdc/Tmd Consortium Network, I. a. f. D. R., 
& Orofacial Pain Special Interest Group, I. A. f. t. S. o. P. (2014). Diagnostic Criteria for 
Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: Recommendations of 
the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. Journal of 
Oral and Facial Pain and Headache, 28, 6-27. https://doi.org/10.[ZIP_CODE]/jop.1151 
Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for 
assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 
15(6), 657-680. https://doi.org/10.1007/BF01068419 
Singh, M. K., Giles, L. L., & Nasrallah, H. A. (2006). Pain insensitivity in schizophrenia: trait or state marker? J 
Psychiatr Pract, 12(2), 90-102. https://doi.org/10.1097/00131746-200603000-[ZIP_CODE] 
Spi[INVESTIGATOR_2996], C. D., Gorusch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1983). Manual for the State-Trait 
Anxiety Inventory (Form Y1). Consulting Psychologists Press. 
Spi[INVESTIGATOR_626], R. L., Kroenke, K., Williams, J. B., & Löwe, B. ( 2006). A brief measure for assessing generalized anxiety 
disorder: the GAD-7. Archives of Internal Medicine, 166(10), 1092-1097. IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
45 of 46
Stack, B. C., Jr. , & Stack, B. C., Sr. . (1992). Temporomandibular joint disorder. American Family Physician, 46, 
143-150. 
Stone, A. A., Broderick, J. E., Porter, L. S., & Kaell, A. T. (1997). The experience of rheumatoid arthritis pain and 
fatigue: examining momentary reports and correlates over one week. Arthritis Care and Research, 10(3), 
185-193. 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9
335630 
Thompson-Hollands, J., Bentley, K. H., Gallagher, M. W., Boswell, J. F., & Barlow, D. H. (2014). Credibility and 
Outcome Expectancy in the Unified Protocol: Relationship to Outcomes. Journal of Experimental 
Psychopathology, 5(1), 72-82. https://doi.org/10.5127/jep.033712 
Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., Cleeland, C., Dionne, R., Farrar, 
J. T., Galer, B. S., Hewitt, D. J., Jadad, A. R., Katz, N. P., Kramer, L. D., Manning, D. C., McCormick, C. G., 
McDermott, M. P., McGrath, P., Quessy, S., Rappaport, B. A., Robinson, J. P., Royal, M. A., Simon, L., 
Stauffer, J. W., Stein, W., Tollett, J., & Witter, J. (2003). Core outcome domains for chronic pain clinical 
trials: IMMPACT recommendations. Pain, 106(3), 337-345. https://doi.org/S030439590300335X [pii] 
Turk, D. C., Meichenbaum, D., & Genest, M. (1983). Pain and Behavioral Medicine. A Cognitive-Behavioral 
Perspective. Guilford Press. 
Turner, J. A., & Romano, J. M. (2001). Cognitive-behavioral therapy for chronic pain. In J. D. Loeser (Ed.), Bonica’s 
management of pain (pp. 1751-1758). Lippi[INVESTIGATOR_4431] & Wilkins. 
Von Korff, M. R., Ormel, J., Keefe, F. J., & Dworkin, S. F. (1992). Grading the severity of chronic pain. Pain, 50(2), 
133-149. https://doi.org/0304-3959(92)[ZIP_CODE]-4 [pii] 
Vowles, K. E., McNeil, D. W., Gross, R. T., McDaniel, M. L., Mouse, A., Bates, M., Gallimore, P., & McCall, C. 
(2007). Effects of pain acceptance and pain control strategies on physical impairment in individuals with 
chronic low back pain. Behavior Therapy, 38(4), 412-425. https://doi.org/S0005-7894(07)[ZIP_CODE]-8 [pii] 
10.1016/j.beth.2007.02.001 IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023
Mobile Application Treatment Program for TMD: Feasibility Trial
Protocol 20-014-E (Supplement)
46 of 46IRB Review
IRB NUMBER: 23-052-1
IRB APPROVAL DATE: 03/29/2023